A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors (Q33378668)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors |
scientific article |
Statements
1 reference
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors (English)
1 reference
John M Maris
1 reference
Elizabeth Fox
1 reference
Brigitte C Widemann
1 reference
Wendy Goodspeed
1 reference
Anne Goodwin
1 reference
Marie Kromplewski
1 reference
Molly E Fouts
1 reference
Diane Medina
1 reference
Andrew Krivoshik
1 reference
Anne E Hagey
1 reference
Peter C Adamson
1 reference
1 February 2008
1 reference
1 reference
14
1 reference
1111-1115
1 reference
Identifiers
1 reference
1 reference